Concentration of benzydamine in vaginal mucosa following local application: an experimental and clinical study.
The results of an experimental and clinical study on the benzydamine binding and distribution in vaginal mucosa are presented, employing benzydamine solution for gynaecological use. When applied first to rats, the mean amount of the drug in their vaginal mucosa became 3.65 +/- 2.99 micrograms/g of fresh tissue with a significant difference between control and treated animals, without detectable amounts in the plasma. When applied to humans, the mean amount of benzydamine assayed in 17 specimens of vaginal mucosa was 9.72 +/- 6.24 micrograms/g. It was greater than the range of animal anti-inflammatory concentration (2-8 micrograms/g) established by pharmacological studies on this drug and justified the local benefits from benzydamine treatment of vaginal inflammation. Benzydamine assayed in seven volunteers with healthy vaginas showed that the drug cannot be detected in the plasma.
D000042:Absorption; D000282:Administration, Intravaginal; D000818:Animals; D001591:Benzydamine / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D005260:Female; D005831:Genital Diseases, Female / Q000601:surgery; D006801:Humans; D011720:Pyrazoles / Q000378:metabolism*; D051381:Rats; D013050:Spectrometry, Fluorescence; D014621:Vagina / Q000378:metabolism*
D011720:Pyrazoles; D001591:Benzydamine